Business Context and Reporting Period
Company: Repligen Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended December 31, 2006
Business Overview: Repligen is a biopharmaceutical company focused on developing novel therapeutics for central nervous system diseases. Commercial revenue is derived from Protein A products for monoclonal antibody purification and SecreFlo for pancreatic disorder assessment.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2006 | Nine Months Ended Dec 31, 2006 |
|---|---|---|
| Total Revenue | $3,882,439 | $10,375,427 |
| Net Income (Loss) | $(19,709) | $(782,294) |
| Operating Loss | $(256,989) | $(1,474,029) |
| Cash and Cash Equivalents | $5,288,248 (as of Dec 31, 2006) | |
| Total Marketable Securities | $16,635,836 (Short-term: $14.2M; Long-term: $2.4M) | |
| Working Capital | $19,695,041 | |
| Stock-Based Compensation Expense | $136,643 | $640,654 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 30% ($894,000) for the three months ended Dec 31, 2006, compared to the prior year, driven primarily by higher product sales volume. For the nine-month period, revenue increased 3% ($349,000).
- Operating Expenses: Total operating expenses rose 22% ($745,000) in the quarter and 16% ($1.6M) for the nine months.
- R&D: Increased 36% in the quarter and 19% for the nine months, largely due to higher clinical trial expenses.
- SG&A: Increased 24% in the quarter and 22% for the nine months, driven by personnel costs and the adoption of SFAS No. 123R (stock-based compensation).
- Profitability: The company reported a net loss of $19,709 for the quarter, compared to a loss of $202,312 in the prior year quarter. For the nine months, the company reported a net loss of $782,294, compared to a net income of $1,516,506 in the prior year. The prior year nine-month income included a one-time $1.17M gain from a settlement with ChiRhoClin.
- Cash Flow: Net cash used in operating activities was $265,909 for the nine months ended Dec 31, 2006, compared to cash provided by operating activities of $175,481 in the prior year period.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash and investment balances ($21.9M total) are adequate to meet needs for at least the next 24 months. Future capital requirements depend on clinical study success and R&D progress.
- Product Lifecycle: The company will cease marketing SecreFlo once supplies provided by ChiRhoClin are depleted. Future revenue will rely on Protein A sales and potential new therapeutic candidates.
- Legal Proceedings:
- ImClone: A summary judgment was issued in favor of Repligen and MIT regarding patent infringement claims over Erbitux production. Repligen intends to seek damages.
- Bristol-Myers Squibb: A lawsuit regarding the '941 patent for Orencia is ongoing, with jury selection scheduled for April 2008.
- Accounting Changes: The company adopted SFAS No. 123R effective April 1, 2006, resulting in the recognition of stock-based compensation expense that was previously not recorded.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $21.9M cash position against projected R&D and clinical trial burn rates.
- Customer Concentration: Note that two customers accounted for 42% and 33% of product revenue in the quarter; assess dependency risks.
- Legal Outcomes: Monitor the status of the ImClone and Bristol-Myers Squibb litigation for potential future revenue or damages.
- SecreFlo Phase-out: Confirm the timeline for the depletion of ChiRhoClin-supplied SecreFlo inventory and its impact on future revenue streams.
- Stock-Based Compensation: Review the impact of the $1.46M unrecognized compensation cost on future earnings.